Standard

SERIES "RATIONAL USE OF ANTI-TUBERCULOSIS DRUGS" Edited by G. B Migliori and D. Manissero Number 1 in this Series Prevalence of inappropriate tuberculosis treatment regimens: a systematic review. / Langendam, M. W.; van der Werf, M. J.; Huitric, E. et al.

In: European respiratory journal, Vol. 39, No. 4, 2012, p. 1012-1020.

Research output: Contribution to journalReview articleAcademicpeer-review

Harvard

APA

Vancouver

Author

BibTeX

@article{4d9c102fa9194afebe528537e16850da,
title = "SERIES {"}RATIONAL USE OF ANTI-TUBERCULOSIS DRUGS{"} Edited by G. B Migliori and D. Manissero Number 1 in this Series Prevalence of inappropriate tuberculosis treatment regimens: a systematic review",
abstract = "A potential threat to the success of new tuberculosis (TB) drugs is the development of resistance. Using drugs in appropriate regimens, such as those recommended in the World Health Organization (WHO) treatment guidelines, prevents the development of resistance. We performed a systematic review to assess the prevalence of inappropriate prescription of TB drugs for the treatment of TB. MEDLINE, EMBASE and other databases were searched for relevant articles in January 2011. Observational studies published from 2000 that included TB patients receiving treatment were selected. A treatment regimen was considered inappropriate if the regimen was not a WHO recommended regimen. 37 studies were included. Inappropriate treatment regimens were prescribed in 67% of studies. The percentage of patients receiving inappropriate regimens varied between 0.4% and 100%. In 19 studies the quality of treatment regimen reporting was low. Despite the fact that assessment of inappropriate treatment was hampered by low quality of reporting, our data indicate a reasonable amount of inappropriate prescription of TB treatment regimens. Thus, there is a risk that new drugs will be used in inappropriate treatment regimens, even with WHO guidelines in place, introducing the risk of resistance development. This article highlights the need to improve implementation of the WHO treatment of TB guidelines",
author = "Langendam, {M. W.} and {van der Werf}, {M. J.} and E. Huitric and D. Manissero",
year = "2012",
doi = "10.1183/09031936.00125511",
language = "English",
volume = "39",
pages = "1012--1020",
journal = "European respiratory journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "4",

}

RIS

TY - JOUR

T1 - SERIES "RATIONAL USE OF ANTI-TUBERCULOSIS DRUGS" Edited by G. B Migliori and D. Manissero Number 1 in this Series Prevalence of inappropriate tuberculosis treatment regimens: a systematic review

AU - Langendam, M. W.

AU - van der Werf, M. J.

AU - Huitric, E.

AU - Manissero, D.

PY - 2012

Y1 - 2012

N2 - A potential threat to the success of new tuberculosis (TB) drugs is the development of resistance. Using drugs in appropriate regimens, such as those recommended in the World Health Organization (WHO) treatment guidelines, prevents the development of resistance. We performed a systematic review to assess the prevalence of inappropriate prescription of TB drugs for the treatment of TB. MEDLINE, EMBASE and other databases were searched for relevant articles in January 2011. Observational studies published from 2000 that included TB patients receiving treatment were selected. A treatment regimen was considered inappropriate if the regimen was not a WHO recommended regimen. 37 studies were included. Inappropriate treatment regimens were prescribed in 67% of studies. The percentage of patients receiving inappropriate regimens varied between 0.4% and 100%. In 19 studies the quality of treatment regimen reporting was low. Despite the fact that assessment of inappropriate treatment was hampered by low quality of reporting, our data indicate a reasonable amount of inappropriate prescription of TB treatment regimens. Thus, there is a risk that new drugs will be used in inappropriate treatment regimens, even with WHO guidelines in place, introducing the risk of resistance development. This article highlights the need to improve implementation of the WHO treatment of TB guidelines

AB - A potential threat to the success of new tuberculosis (TB) drugs is the development of resistance. Using drugs in appropriate regimens, such as those recommended in the World Health Organization (WHO) treatment guidelines, prevents the development of resistance. We performed a systematic review to assess the prevalence of inappropriate prescription of TB drugs for the treatment of TB. MEDLINE, EMBASE and other databases were searched for relevant articles in January 2011. Observational studies published from 2000 that included TB patients receiving treatment were selected. A treatment regimen was considered inappropriate if the regimen was not a WHO recommended regimen. 37 studies were included. Inappropriate treatment regimens were prescribed in 67% of studies. The percentage of patients receiving inappropriate regimens varied between 0.4% and 100%. In 19 studies the quality of treatment regimen reporting was low. Despite the fact that assessment of inappropriate treatment was hampered by low quality of reporting, our data indicate a reasonable amount of inappropriate prescription of TB treatment regimens. Thus, there is a risk that new drugs will be used in inappropriate treatment regimens, even with WHO guidelines in place, introducing the risk of resistance development. This article highlights the need to improve implementation of the WHO treatment of TB guidelines

U2 - 10.1183/09031936.00125511

DO - 10.1183/09031936.00125511

M3 - Review article

C2 - 22005923

VL - 39

SP - 1012

EP - 1020

JO - European respiratory journal

JF - European respiratory journal

SN - 0903-1936

IS - 4

ER -

ID: 1505587